Table of contents

Electronic pages

• Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID) (22 April, 2020)

  Alessandro Giollo, Giovanni Adami, Davide Gatti, Luca Idolazzi, Maurizio Rossini
• Non-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: ‘Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)’ by Giollo et al

  (30 April, 2020)

  Sara Monti, Carlomaurizio Montecucco
• COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs (15 May, 2020)

  Edoardo Conticini, Elena Bargagli, Marco Bardelli, Giuseppe Domenico Rana, Caterina Baldi, Paolo Cameli, Stefano Gentileschi, David Bennett, Paolo Falsetti, Nicola Lanzarone, Francesca Bellisai, Cristiana Barreca, Roberto D'Alessandro, Luca Cantarini, Bruno Frediani
• Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: ‘COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs’ by Conticini et al

  (15 May, 2020)

  Sara Monti, Carlomaurizio Montecucco
• Rheumatic diseases in intensive care unit patients with COVID-19 (20 May, 2020)

  Sergey Moiseev, Sergey Avdeev, Michail Brovko, Andrey Yavorovskiy, Pavel I Novikov, Karina Umbetova, Larisa Akulkina, Natal'ya Tsareva, Victor Fomin
• Comorbidities and rheumatological diseases at the time of COVID-19. Response to: ‘Rheumatic diseases in intensive care unit patients with COVID-19’ by Moiseev et al

  (20 May, 2020)

  Sara Monti, Carlomaurizio Montecucco
• What is the true incidence of COVID-19 in patients with rheumatic diseases? (22 April, 2020)

  Ennio Giulio Favalli, Francesca Ingegnoli, Rolando Cimaz, Roberto Caporali
• Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)? (21 April, 2020)

  Sergey Moiseev, Sergey Avdeev, Michail Brovko, Pavel Novikov, Victor Fomin
• Response to ‘Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?’ by Moiseev et al

  (28 April, 2020)

  Francesca Romana Spinelli, Fulvia Ceccarelli, Manuela Di Franco, Fabrizio Conti
• Patients with lupus are not protected from COVID-19 (24 April, 2020)

  Amr H Sawalha
• No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: comment by Joob and Wiwanitkit (13 May, 2020)

  Vasco C. Romão, Ana Rita Cruz-Machado, João Eurico Fonseca
• SLE patients are not immune to covid-19: importance of sending the right message across (23 April, 2020)

  Mohit Goyal
• Response to: ‘Patients with lupus are not protected from COVID-19: a comment’ by Sawalha, ‘No evidence so far on the protective effect of hydroxycloroquin to prevent COVID-19: response to the Comment by Joob and Wiwanitkit’ by Romão et al and ‘SLE patients are not immune to COVID-19: importance of sending the right message across’ by Goyal

  (13 May, 2020)

  Beuy Joob, Viroj Wiwanitkit
• Are patients with systemic lupus erythematosus at increased risk for COVID-19? (25 May, 2020)

  Ennio Giulio Favalli, Maria Gerosa, Antonella Murgo, Roberto Caporali
• Response to: ‘Are patients with systemic lupus erythematosus at increased risk for COVID-19?’ by Favalli et al

  (25 May, 2020)

  Alexis Mathian, Zahir Amoura
• Correction: Knee osteoarthritis risk in non-industrial societies undergoing an energy balance transition: evidence from the indigenous Tarahumara of Mexico

  (12 January, 2021)
• Correction: High prevalence of spondyloarthritis-like MRI lesions in postpartum women: a prospective analysis in relation to maternal, child and birth characteristics

  (12 January, 2021)